BPC-157 Human Trials: What Has Actually Been Published

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

BPC-157 has a large preclinical literature and a very small human one. A PROSPERO-registered systematic review searching Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to June 2026 identified three human studies with 30 participants in total, and rated the overall certainty of evidence as very low (Poolton et al., 2026). This article sets out what those studies were and what the gap means.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Key points

Three human studies, 30 participants combined, all judged poor methodological quality.
Certainty of evidence rated very low for serious risk of bias, indirectness and imprecision.
None used a standardised pharmaceutical preparation.
The review’s conclusion was that clinical use outside regulated trials is not supported.
The preclinical literature is extensive but dominated by one research network.

The three studies

Study type	Participants	Setting
Retrospective study of intra-articular administration for knee pain	16	Record review, no control group
Retrospective pilot in interstitial cystitis	12	Record review, no control group
Prospective intravenous safety pilot	2	Safety-focused (Lee et al., 2025)

The review used the NIH quality assessment tool for before-after studies with no control group, and the GRADE framework for certainty. All three studies reported symptom improvement in most participants without treatment-related adverse events, but with that design and those numbers, improvement cannot be separated from natural history, regression to the mean or expectation effects.

Why 30 participants is not a small trial, but no trial

The issue is not only sample size. Two of the three studies were retrospective, meaning the data were collected for other purposes and reviewed afterwards. None had a control group. A single-arm study in a condition that fluctuates cannot attribute change to the intervention. GRADE downgrades such evidence heavily for exactly this reason, which is how three studies reporting improvement still produce a “very low certainty” rating.

GRADE concern	What it means here
Risk of bias	Retrospective, uncontrolled, unblinded
Indirectness	Populations and administration routes differ from each other
Imprecision	Very small numbers produce wide uncertainty

What is blocking larger trials

A 2026 biopharmaceutical review examined BPC-157 from a drug development perspective and concluded that the main barrier is not absence of biological activity but absence of fundamental pharmaceutical science. It noted no approved formulation, no validated dosing regimen, no completed Phase II trial, no BCS classification data, no permeability characterisation and no formal excipient-compatibility studies. Available clinical data came from fewer than 30 subjects across three uncontrolled pilot studies, none using standardised preparations (Mateescu et al., 2026). A 2025 narrative review reached a similar position for musculoskeletal applications, noting broad preclinical support alongside extremely limited human data (McGuire et al., 2025).

The preclinical picture, for contrast

The contrast with the animal literature is stark. The 2003 rat Achilles tendon study reported improvements across biomechanical, functional, microscopic and macroscopic measures over 14 days (Staresinic et al., 2003), and many similar studies followed. A formal two-species ADME study established a plasma half-life under 30 minutes with linear kinetics, and found intramuscular bioavailability of roughly 14–19% in rats versus 45–51% in dogs (He et al., 2022). That threefold species difference in a basic pharmacokinetic parameter is itself a warning against extrapolating rodent results.

Evidence type	Volume	Quality
Cell and tissue studies	Extensive	Mechanistic, model-specific
Rodent injury models	Many	Consistent direction; limited independent replication
Formal pharmacokinetics	One two-species study	Good
Human studies	3 studies, n = 30	Very low certainty

What this means for laboratory work

For researchers the absence of human data is not a problem to be argued around; it is the reason the compound is interesting to study. It also sets expectations for what a laboratory result can support. An in-vitro or animal finding adds to the preclinical column of the table above, which is already well populated. The sparse columns are formulation science, independent replication and controlled human work.

Our BPC-157 research peptide is supplied for laboratory research. Certificates are available for listed products — contact us for the latest report. Background: what is BPC-157? and BPC-157 half-life.

Open questions

Will any sponsor fund the formulation and pharmacokinetic work a proper trial would require?
Can the rodent findings be replicated by groups unconnected to the original network?
Which indication, if any, has preclinical data strong enough to justify a controlled trial?

Frequently asked questions

Have there been human trials of BPC-157?

A systematic review searching four databases to June 2026 found three human studies with 30 participants in total: two retrospective case series and one prospective intravenous safety pilot with two participants.

What did the systematic review conclude?

All three studies were judged to be of poor methodological quality, and overall certainty of evidence was rated very low because of serious risk of bias, indirectness and imprecision.

Was BPC-157 ever in formal clinical development?

A 2003 paper notes it was then in clinical trials for inflammatory bowel disease under a development code. No such programme has produced an approved product.

Why is there so little human data?

A 2026 biopharmaceutical review identifies the barrier as the absence of fundamental pharmaceutical science: no characterised formulation, no validated pharmacokinetics and no coherent development strategy.

Does animal evidence substitute for human trials?

No. Preclinical results indicate what to test, not what will happen in people. Species differences in this case are documented: intramuscular bioavailability differed roughly threefold between rats and dogs.